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Abstract
To our knowledge, no phase III study has reported the safety of adjuvant chemotherapy with SOX (S-1 with
oxaliplatin) in patients with colorectal cancer. We report the results of a planned safety analysis of the
ACTS-CC 02 trial (Randomized phase III study of S-1/Oxaliplatin comparing Tegafur-Uracil/Leucovorin in the
Adjuvant Chemotherapy of Stage IIIb Colorectal Cancer), which was a randomized phase III trial of SOX versus
tegafur and uracil with leucovorin. The incidence of adverse events associated with SOX was acceptable.
Background: This trial was designed to verify the superiority of 6 months of postoperative adjuvant chemotherapy
with SOX (S-1 with oxaliplatin) with UFT (tegafur and uracil) with LV (leucovorin) in terms of disease-free survival in
patients with high-risk stage III colon cancer. We report the results of a planned safety analysis. Patients and
Methods: Patients who underwent curative resection for high-risk stage III colon cancer (any T, N2, or positive nodes
around the origin of the feeding arteries) were randomly assigned to receive either UFT/LV (300-600 mg/d UFT with
75 mg/d LV on days 1-28, every 35 days, for 5 cycles) or SOX (100 mg/m2 of oxaliplatin on day 1 with 80-120 mg/d S-1
on days 1-14, every 21 days, for 8 cycles). Treatment status and safety were evaluated. Results: A total of 966
patients were enrolled, and 932 patients were included in safety analyses. The planned 6-month protocol treatment
was received by 76.9% of the patients in the UFT/LV group and 65.8% of those in the SOX group. The overall
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incidence of any Grade adverse events (AEs) were 91.3% in the UFT/LV group and 98.7% in the SOX group, and those
of Grade  3 AEs were 16.1% and 36.1%, respectively. As for Grade  3 AEs, leukopenia, neutropenia,
thrombocytopenia, and sensory neuropathy were more common in the SOX group. The incidence of Grade  3
sensory peripheral neuropathy was 4.6% in the SOX group. Conclusion: The completion rate of adjuvant SOX and its
incidence of AEs were acceptable in patients with colon cancer.
Clinical Colorectal Cancer, Vol. 17, No. 2, e153-61 ª 2018 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Adverse events, L-OHP, Oral ﬂuorouracil, Sensory peripheral neuropathy, Tegafur/gimeracil/oteracil
Introduction
Postoperative adjuvant chemotherapy has been shown to improve
outcomes in patients with stage III colon cancer and is considered
the global standard treatment for this disease.
In Japan, convenient oral FU (ﬂuoropyrimidine) preparations have
been the treatment of choice. Two phase III studies of adjuvant
chemotherapy with oral FUs in Japanese patients with stage III colon
cancer (JCOG0205 [A Trial Comparing Adjuvant Oral UFT/LV to
5-FU/l-LV in Stage III Colorectal Cancer] and ACTS-CC [Adjuvant
Chemotherapy Trial of S-1 for Colon Cancer 02]), most of whom
underwent D3 lymph node (LN) dissection,1 have reported good
treatment outcomes. In the JCOG0205 study, which showed the
noninferiority of UFT (tegafur and uracil) with LV (leucovorin) to
intravenous bolus 5-FU (5-ﬂuorouracil) with LV (5-FU/LV),2 and
the ACTS-CC study, which showed that S-1 is noninferior to
UFT/LV3; the 5-year disease-free survival (DFS) rates were approxi-
mately 70%, and the 5-year overall survival rates were approximately
85%. Because the risk of recurrence and adverse events (AEs) asso-
ciated with oxaliplatin, monotherapy with FUs is considered an op-
tion for adjuvant therapy in patients with stage III colon cancer.
However, stage III disease includes subgroups of patients with very
poor outcomes. In the JCOG0205 study, the 5-year DFS rate was
90.4% in patients with stage IIIA disease, whereas it was 74.1% in
patients with stage IIIB disease and 58.9% in those with IIIC disease.
In such “high-risk” subgroups of patientswith stage III disease, there is
room for further improvement in outcomes. More aggressive regi-
mens including oxaliplatin are expected to be effective. A subgroup
analysis of the patients with stage II or III colon cancer who were
enrolled in the MOSAIC (Multicenter International Study of Oxa-
liplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer) study
showed that oxaliplatin was beneﬁcial in patients withN2 disease.4 At
present, 6 months of regimens combining FUs with oxaliplatin have
been widely used in Western countries.5-9 The Japanese Society for
Cancer of the Colon and Rectum Guidelines 2016 have recom-
mended 5-FU/LV, UFT/LV, capecitabine, and S-1 in addition to the
oxaliplatin-based regimens of FOLFOX (infusional 5-FU/LV with
oxaliplatin) and CapeOX (capecitabine with oxaliplatin).10
S-1 is an oral FU that combines tegafur (a prodrug of 5-FU) with
gimeracil and oteracil potassium. Gimeracil more strongly inhibits
dihydropyrimidine dehydrogenase than uracil in UFT, thereby
more strongly suppressing 5-FU degradation. S-1 includes oteracil
potassium to reduce gastrointestinal toxicity.11 S-1 has the advan-
tage of a lower incidence of hand-foot syndrome than capecita-
bine,12 which is the most widely used oral FU in Western countries.
We therefore focused on treatment with SOX (S-1 with oxaliplatin)
as a new oxaliplatin-based regimen for adjuvant chemotherapy. As
ﬁrst-line treatment for metastatic colorectal cancer (mCRC), SOX
has been shown to be noninferior to CapeOX,13 and SOX with
bevacizumab has been reported to be noninferior to infusional
modiﬁed 5-FU/LV with oxaliplatin with bevacizumab.14 However,
the efﬁcacy and safety of SOX as adjuvant chemotherapy for colo-
rectal cancer remain to be conﬁrmed.
We conducted the ACTS-CC 02 trial to validate the therapeutic
usefulness of oxaliplatin-based adjuvant chemotherapy in patients
with high-risk stage III colon cancer in Japan as well as to verify the
efﬁcacy and safety of adjuvant chemotherapy with SOX in patients
with colon cancer. Patients in the control arm received UFT/LV,
the regimen most commonly used for adjuvant chemotherapy in
Japan. This randomized phase III study was designed to verify the
superiority of SOX in terms of DFS.
Because no phase III study has reported the safety of adjuvant
chemotherapy with SOX in patients with colorectal cancer, we now
report the results of a planned safety analysis.
Patients and Methods
Patients
This study was conducted in accordance with the ethical prin-
ciples of the Declaration of Helsinki and in compliance with
Japanese ethical guidelines for clinical studies. The study protocol
was approved by the institutional review board of each participating
institution. Written informed consent was obtained from all
patients before enrollment.
The main inclusion criteria were as follows: tumors located in the
colon or the upper rectum, histologically conﬁrmed high-risk stage
III adenocarcinoma (any T, N2, or positive main LNs as deﬁned
below) after R0 resection, an age of 20 to 80 years, an Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of
0 or 1, no previous chemotherapy or radiotherapy, adequate oral
intake, preserved major organ functions, no other active malig-
nancies, and no uncontrollable severe infection.
Main LNs are deﬁned in the Japanese Classiﬁcation of Colorectal
Carcinoma, seventh edition as LNs around the origin of the feeding
artery (ie, the ileocolic, right colic, middle colic, or inferior mesenteric
artery; see Supplemental Figure 1 in the online version).15
Randomization and Masking
Participants were randomly assigned in a 1:1 ratio to receive
either UFT/LV or SOX. Randomization was done centrally with
the use of the minimization method and the following stratiﬁcation
factors: tumor location (colon or upper rectum), the number of
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positive LNs (4-6 positive LNs, or  7 positive LNs or main LNs
positive), and institution. The randomization sequence was gener-
ated by a team (EPS Corporation, Tokyo, Japan) independently of
the trial sponsor and investigators, who used a validated computer
system. Local investigators used a Web-based system for enrollment,
which then automatically assigned patients to treatment groups.
Participants, investigators, and data analysts were not masked to the
treatment assignments because we compared an oral-based regimen
with an infusional regimen.
Treatment
In the UFT/LV group, UFT (body surface area
[BSA] < 1.17 m2, 300 mg; BSA  1.17 m2 to  1.49 m2, 400 mg;
BSA  1.50 m2 to  1.83 m2, 500 mg; BSA > 1.83 m2, 600 mg)
and LV (75 mg per patient) were orally administered daily in
3 divided doses (every 8 hours) for 28 consecutive days, followed by
a 7-day rest. This 5-week treatment comprised 1 cycle. A total of
5 cycles (25 weeks) were delivered.
In the SOX group, S-1 (BSA < 1.25 m2, 80 mg; BSA  1.25 m2
to < 1.5 m2, 100 mg; BSA  1.5 m2, 120 mg) was orally
administered twice daily from after dinner on day 1 to after
breakfast on day 15, followed by a 7-day rest. Oxaliplatin
(100 mg/m2) was infused intravenously over the course of 2 hours
on day 1 of each cycle. This 3-week treatment comprised 1 cycle.
A total of 8 cycles (24 weeks) were delivered.
If the treatment schedule was delayed because of the withdrawal
of drugs because of AEs in either treatment group, the protocol
treatment was considered to be completed 6 months from the day of
starting treatment. After completing the study treatment, patients
were followed-up without any further treatment unless recurrence
or secondary cancer developed.
The treatment was started within 8 weeks after surgery. At the
initiation of each treatment cycle, patients were conﬁrmed to
meet all of the following criteria for starting treatment: white cell
count  3.0  103/mL, neutrophil count  1500/mL, platelet
count  75  103/mL, hemoglobin level  9.0 g/dL, serum
aspartate aminotransferase (AST) level  100 U/L, serum alanine
aminotransferase (ALT) level  100 U/L, serum total bilirubin
level  2.0 mg/dL, serum creatinine level < 1.5 mg/dL, and
Grade  1 anorexia, nausea, vomiting, diarrhea, mucositis, and
stomatitis. In the SOX group, only S-1 was given to patients with
Grade 3 sensory neuropathy, and treatment with SOX was not
possible in patients with a creatinine clearance of < 60 mL/min. In
patients who met the following criteria, treatment was restarted at a
1-level lower dose after recovery: white cell count < 2.0  103/mL,
neutrophil count < 1000/mL, platelet count < 50  103/mL,
hemoglobin level < 8.0 g/dL, serum AST level > 150 U/L, serum
ALT level > 150 U/L, total bilirubin level > 2.5 mg/dL, or
Grade  3 anorexia, nausea, vomiting, diarrhea, mucositis, or
stomatitis. In the SOX group, however, even if the platelet count
was between  50  103/mL and < 75  103/mL, only the dose of
oxaliplatin was reduced by 1 level.
Evaluations
Adverse events, including the results of laboratory tests, were
assessed at the initiation of each treatment cycle. Reporting the
worst grade of the following AEs was mandatory: white cell count,
neutrophil count, platelet count, hemoglobin level, serum AST
level, serum ALT level, total bilirubin level, serum creatinine level,
nausea, vomiting, diarrhea, anorexia, fatigue, rash, desquamation,
pigmentation, mucositis, stomatitis, and sensory neuropathy. The
contents and grades of AEs were evaluated according to the National
Figure 1 Consolidated Standards of Reporting Trials Diagram
Control arm
Total enrollment n = 966
Excluded n = 6
Informed consent withdrawn : n = 5
Ethical guideline violation: n = 1
SOX n = 482
No treatment n = 6
Full analysis set n = 478
UFT/LV n = 484
No treatment n = 18
Excluded n = 4
Informed consent withdrawn : n = 4
Full analysis set n = 478
Test arm
Safety analysis set n = 472 Safety analysis set n = 460
Abbreviations: SOX ¼ S-1 with oxaliplatin; UFT/LV ¼ tegafur and uracil with leucovorin.
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Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0.
Statistical Analysis
From the results of previous studies,7,8 we estimated that the
3-year DFS rate would be 65% in the UFT/LV group and 71.5% in
the SOX group in the present study. We therefore expected that the
3-year DFS rate would be 6.5 percentage points higher in the SOX
group (hazard ratio, 0.78). We estimated that we would need to
enroll a total of 1186 patients in 3 years to have a statistical power of
80% (2-sided a value of 0.05) to detect a difference between the
groups after 3 years of follow-up. Taking into account dropout
patients, we set the target number of patients at 1200. In this study,
DFS was deﬁned as the period from the day of enrollment in the
study to the day of recurrence, the detection of cancer lesions other
than recurrence, or the day of death, whichever came ﬁrst.
Descriptive statistics such as means, SDs, and medians were
calculated. Fisher exact test was used to compare the incidence of
AEs between the treatment groups. P values of < .05 were
considered to indicate statistical signiﬁcance. The relative perfor-
mance was deﬁned as the ratio of the total drug dose actually
administered to the patient to the total drug dose speciﬁed in the
protocol. Patients who completed the protocol treatment were
deﬁned as those who completed the last dose of the planned pro-
tocol treatment (UFT/LV, 8 cycles; SOX, 5 cycles) or patients in
whom 6 months had elapsed from the time of starting the protocol
treatment. All statistical analyses were performed using SAS soft-
ware, version 9.3 (SAS Institute, Cary, NC).
Results
Patient Characteristics
From April 2010 through October 2014, a total of 966 patients
were enrolled at 260 institutions. Although we extended the
enrollment period, the target number of patients was not attained.
Patients who withdrew informed consent (9 patients), violated the
Japanese ethical guidelines for clinical studies (1 patient), or who
dropped out before receiving the protocol treatment (24 patients)
were excluded, and the remaining 932 patients (472 in the UFT/LV
group and 460 in the SOX group) were included in the safety
analysis set (Figure 1).
The patient characteristics are shown in Table 1. The median
age was 65 (range, 26-80) years, and 878 patients (94.2%) had






Median (range) 66 (32-80) 65 (26-80)
Sex
Male 252 (53.4) 253 (55.0)
Female 220 (46.6) 207 (45.0)
ECOG PS
0 449 (95.1) 429 (93.3)
1 23 (4.9) 31 (6.7)
Tumor Location
Right colon (C, A, T) 190 (40.3) 171 (37.2)
Left colon (D, S) 130 (27.5) 139 (30.2)
Rectosigmoid 90 (19.1) 85 (18.5)
Upper rectuma 62 (13.1) 65 (14.1)
Histological Type
Papillary 10 (2.1) 3 (0.7)
Tubular 409 (86.7) 409 (88.9)
Poorly, mucinous, signet 53 (11.2) 48 (10.4)
Depth of Tumor Invasion
T1 8 (1.7) 6 (1.3)
T2 16 (3.4) 20 (4.3)
T3 293 (62.1) 283 (61.5)
T4a 125 (26.5) 130 (28.3)
T4b 30 (6.4) 21 (4.6)
Lymphatic Invasion
Negative 52 (11.0) 53 (11.5)
Positive 420 (89.0) 407 (88.5)
Venous invasion
Negative 97 (20.6) 97 (21.1)
Positive 375 (79.4) 363 (78.9)
Scope of LN Dissection
D2 56 (11.9) 32 (7.0)
D3 416 (88.1) 428 (93.0)
LNs Examined, n
Median (range) 21 (0-96) 22 (0-107)
<12 62 (13.1) 47 (10.2)




Median (range) 5 (1-22) 5 (1-39)
4-6 283 (60.0) 274 (59.6)
7 or main LN positive 189 (40.0) 186 (40.4)
LN Metastasis
N1a (1 positive LN) 1 (0.2) 4 (0.9)
N1b (2-3 positive LN) 17 (3.6) 22 (4.8)
N2a (4-6 positive LN) 317 (67.2) 305 (66.3)
N2b (7 positive LN) 137 (29.0) 129 (28.0)
Stage






IIIB 242 (51.3) 226 (49.1)
IIIC 224 (47.5) 228 (49.6)
Data are presented as n (%) except where otherwise stated.
Abbreviations: A ¼ ascending colon; C ¼ cecum; D ¼ descending colon; ECOG ¼ Eastern
Cooperative Oncology Group; LN ¼ lymph node; PS ¼ performance status; S ¼ sigmoid colon;
T ¼ transverse colon.
aIncluding patients in whom the lower edge of the tumor is in the upper rectum proximal to the
peritoneal reﬂection.
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Figure 2 Treatment Status According to Cycle
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Abbreviations: SOX ¼ S-1 with oxaliplatin; UFT/LV ¼ tegafur and uracil with leucovorin.
Table 2 Adverse Events (Safety Analysis Set)
UFT/LV (n [ 472) SOX (n [ 460)
P (Grade ‡3)
Any Grade ‡3 Any Grade ‡3
n (%) n (%) n (%) n (%)
Patients With at Least 1 AE 431 (91.3) 76 (16.1) 454 (98.7) 166 (36.1)
Laboratory Findings
Leukopenia 111 (23.5) 0 (0.0) 271 (58.9) 5 (1.1) .0290
Neutropenia 74 (15.7) 7 (1.5) 271 (58.9) 79 (17.2) <.0001
Thrombocytopenia 76 (16.1) 3 (0.6) 324 (70.4) 13 (2.8) .0111
Anemia 117 (24.8) 3 (0.6) 137 (29.8) 2 (0.4) 1.0000
Bilirubin 171 (36.2) 3 (0.6) 195 (42.4) 4 (0.9) .7223
AST 141 (29.9) 10 (2.1) 278 (60.4) 3 (0.7) .0904
ALT 141 (29.9) 14 (3.0) 184 (40.0) 4 (0.9) .0296
Creatinine 34 (7.2) 2 (0.4) 33 (7.2) 0 (0.0) .4995
Clinical Findings
Stomatitis 58 (12.3) 4 (0.8) 101 (22.0) 4 (0.9) 1.0000
Nausea 85 (18.0) 4 (0.8) 190 (41.3) 9 (2.0) .1715
Vomiting 30 (6.4) 0 (0.0) 53 (11.5) 4 (0.9) .0590
Diarrhea 149 (31.6) 38 (8.1) 139 (30.2) 25 (5.4) .1189
Anorexia 113 (23.9) 11 (2.3) 221 (48.0) 16 (3.5) .3327
Fatigue 105 (22.2) 5 (1.1) 209 (45.4) 7 (1.5) .5741
Rash/desquamation 49 (10.4) 2 (0.4) 48 (10.4) 1 (0.2) 1.0000
Hyperpigmentation 47 (10.0) - 92 (20.0) - -
Peripheral sensory neuropathy 15 (3.2) 1 (0.2) 323 (70.2) 21 (4.6) <.0001
Hand-foot syndrome 4 (0.8) 0 (0.0) 8 (1.7) 0 (0.0) -
Abbreviations: AE ¼ adverse event; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; SOX ¼ S-1 with oxaliplatin; UFT/LV ¼ tegafur and uracil with leucovorin.
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Table 3 Incidence of Grade ‡ 3 Adverse Events Occurring During 6 Months of Treatment With Other Regimens Including Oxaliplatin















Dose of Oxaliplatin 100 mg/m2 130 mg/m2 85 mg/m2 85 mg/m2 85 mg/m2 85 mg/m2 130 mg/m2
Total Expected Dose
of Oxaliplatin
800 mg/m2 1040 mg/m2 1020 mg/m2 765 mg/m2 1020 mg/m2 1020 mg/m2 1040 mg/m2
Cumulative Dose of
Oxaliplatin (Median)
625 mg/m2 NA 810 mg/m2 676 mg/m2 672.5 mg/m2 NA NA
Patients With at
Least 1 AE, %
36.1 55 NA NA NA 48.1 41.1
Neutropenia 17.2 9 41.1 NA 28.7 34.2 15.3
Thrombocytopenia 2.8 5 1.7 NA 1.7 0 5.5
Stomatitis 0.9 <1 2.7 NA NA 0.6 0.8
Nausea 2 5 5.1 15.6 1.7 0.6 2.9
Vomiting 0.9 6 5.8 12.1 0.7 0.6 0.8
Diarrhea 5.4 19 10.8 38.1 2.1 0.6 5.5
Peripheral Sensory
Neuropathy
22.4 (Grade 2/3) 11 12.4 30.4 (Grade 2/3) 5.8 36.1 (Grade 2/3) 36.7 (Grade 2/3)
Hand-Foot Syndrome 0.2 (Grade 2/3) 5 2.0 NA NA 2.5 (Grade 2/3) 14.7 (Grade 2/3)
Abbreviations: ACTS-CC 02 ¼ Randomized phase III study of S-1/Oxaliplatin comparing Tegafur-Uracil/Leucovorin in the Adjuvant chemotherapy of Stage IIIb colorectal cancer; CapeOX ¼ capecitabine with oxaliplatin; FLOX ¼ bolus 5-FU/LV with oxaliplatin; FOLFOX4 ¼
infusional 5-FU/LV with oxaliplatin; JFMC41 ¼ A tolerability study in Japan of Oxaliplatin, ﬂuorouracil, and l-leucovorin for patients with stage II/III colon cancer(JFMC41-1001-C2: JOIN Trial); JFMC47 ¼ A Randomized, Multicenter, Phase III Study to Compare 6 Months of either
5-Fluorouracil/l-leucovorin plus Oxaliplatin (mFOLFOX6) or Capecitabine plus Oxaliplatin (XELOX) with 3 Months of either mFOLFOX6 or XELOX as Adjuvant Chemotherapy in Patients with Completely Resected Stage III Colon Cancer (JFMC47-1202-C3: ACHIEVE Trial);
mFOLFOX6 ¼ infusional modiﬁed 5-FU/LV with oxaliplatin; MOSAIC ¼ Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer; NSABP C-07 ¼ Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or




















an ECOG PS of 0. The baseline characteristics were well
balanced.
Treatment Status
The median number of treatment cycles was 5 (range, 1-5) in the
UFT/LV group and 7 (range, 1-8) in the SOX group. The mean
and median relative performances were respectively 83.1% and
100.0% for UFT and 84.7% and 100.0% for LV in the UFT/LV
group and 74.9% and 85.4% for S-1 and 73.6% and 81.3% for
oxaliplatin in the SOX group. The mean and median cumulative
doses of oxaliplatin in the SOX group were 569.3 mg/m2 and 625.0
mg/m2, respectively. The dose of oxaliplatin was reduced in 176 of
the 460 patients in the SOX group.
Figure 2 shows the treatment status in each cycle. The 6-month
protocol treatment was completed in 363 patients (76.9%) in the
UFT/LV group and 303 patients (65.9%) in the SOX group. The
main reasons for discontinuing the protocol treatment in the UFT/
LV group (109 patients) and the SOX group (157 patients) were as
follows: recurrence or secondary cancer in 20 patients (18.3%) and
17 patients (10.8%); difﬁculty in continuing treatment because of
AEs in 33 patients (30.3%) and 45 patients (28.7%); treatment
could not be resumed within 28 days after the last day of previous
treatment in 20 patients (18.3%) and 38 patients (24.2%); and the
patient requested treatment to be discontinued in 30 patients
(27.5%) and 41 patients (26.1%), respectively.
Safety Proﬁle
The incidence of AEs are shown in Table 2. Any Grade AEs
occurred in 431 patients (91.3%) in the UFT/LV group and 454
patients (98.7%) in the SOX group. AEs of Grade  3 occurred in
76 patients (16.1%) in the UFT/LV group and 166 patients
(36.1%) in the SOX group. In the SOX group, oxaliplatin-related
sensory neuropathy of Grade 1 developed in 220 patients
(47.8%), Grade 2 in 82 patients (17.8%), and Grade 3 in 21 pa-
tients (4.6%). No patient experienced Grade 4 sensory neuropathy.
Grade  3 leukopenia, neutropenia, thrombocytopenia, and
peripheral sensory neuropathy occurred more frequently in the SOX
group, whereas Grade  3 elevations of ALT were more common in
the UFT/LV group. Febrile neutropenia did not develop in either
group.
There was 1 treatment-related death: fulminant hepatitis devel-
oped in the second cycle in 1 patient in the UFT/LV group, and the
patient died 14 days after the onset of fulminant hepatitis.
Discussion
We report the results of an interim safety analysis of a phase III
study comparing SOX with UFT/LV as adjuvant therapy in patients
with high-risk stage III colon cancer. The incidence of Grade  3
AEs in the 460 patients who received SOX was 36.1%, which was
higher than the incidence in patients who received UFT/LV
(16.1%), but was considered acceptable. The main cause of the
difference in Grade  3 AEs was neutropenia.
We modiﬁed the dose of oxaliplatin used in our study to enhance
the feasibility (continuity and completion) of adjuvant therapy. In
phase I/II studies of SOX using oxaliplatin at a dose of 130 mg/m2
in patients with mCRC, 27% of the patients had Grade  3
thrombocytopenia.16 Therefore, the dose of oxaliplatin was set at
100 mg/m2 in phase II studies of SOX for advanced gastric cancer.
This dose was highly feasible and effective, and the incidence of
Grade  3 thrombocytopenia was 13%.17 On the basis of these
results, the dose of oxaliplatin in the SOX group of our study was set
at 100 mg/m2. Furthermore, in our study, if the platelet count was
between  50  103/mm3 and < 75  103/mm3, only the dose of
oxaliplatin was decreased by 1 level in the next cycle, and Grade  3
thrombocytopenia developed in only 2.8% of the patients.
The incidence of clinical symptoms such as diarrhea and anorexia
in the SOX group in our study was lower than those in a previous
study in which the dose of oxaliplatin was 130 mg/m2 in patients
with mCRC who received SOX.14 The incidence of AEs in the
SOX group was generally consistent with those reported for FOL-
FOX and CapeOX (ie, 2 other oxaliplatin-based regimens), and
comparable results were obtained (Table 3).7-9,18,19 The incidence
of sensory neuropathy in the SOX group was 17.8% for Grade 2
and 4.6% for Grade 3. These incidence rates are similar to, or
slightly lower than, the incidence rates of Grade 2 and Grade 3
sensory neuropathy reported for FOLFOX and CapeOX.7-9,18,19
These results might also be attributed to the use of oxaliplatin in
a dose of 100 mg/m2. The completion rate of the 6-month protocol
treatment with SOX was 65.9%, which is similar to the completion
rates of the FOLFOX and CapeOX regimens in clinical trials per-
formed in Japan (70% and 59%, respectively).19
The incidence rates of AEs in the UFT/LV group were similar to
the reported incidence rates in previous reports.2,3 Our results
conﬁrmed that liver dysfunction caused by UFT develops in a
certain proportion of patients. The only Grade 3 or higher AE that
was more common in the UFT/LV group than in the SOX group
was elevated ALT levels. In the UFT/LV group, there was 1
treatment-related death. This patient was given UFT/LV without
checking the result of laboratory tests at the start of the second cycle
of treatment. This protocol violation might have led to the non-
detection of early changes associated with liver damage and the
development of fulminant hepatitis, resulting in death. UFT/LV has
a very low incidence of serious AEs and is easy to use, but can cause
severe liver dysfunction. Previous studies have reported that UFT-
related liver dysfunction most commonly develops within 2
months after starting treatment. It is therefore mandatory to check
liver function at the beginning of each cycle of UFT treatment.
Conclusion
The incidence of AEs associated with adjuvant SOX after colon
cancer surgery was considered acceptable. The efﬁcacy results will be
available in 2018.
Clinical Practice Points
 In Japan, because of the risks of recurrence and the AEs asso-
ciated with oxaliplatin, monotherapy with FUs is considered an
option for adjuvant therapy in patients with stage III colon
cancer.
 S-1 is an oral FU that has been already used in Japan in an
adjuvant setting for gastric, pancreatic, and colorectal cancers.
 S-1 with oxaliplatin therapy has also been used to treat advanced
gastric and colorectal cancers.
 We conducted the ACTS-CC 02 trial to validate the therapeutic
usefulness of oxaliplatin-based adjuvant chemotherapy in
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patients with high-risk stage III colon cancer in Japan and to
verify the efﬁcacy and safety of adjuvant chemotherapy with
SOX in patients with colon cancer.
 In the planned safety analysis, the completion rate of adjuvant
SOX and its incidence of AEs were acceptable in patients with
high-risk colon cancer.
 Because no phase III study has reported the safety of adjuvant
chemotherapy with SOX in patients with colorectal cancer, our
results might provide valuable information for the optimal use of
SOX regimens in clinical practice.
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